Exon Skipping Therapies Market Size Reaches $2.81 Billion In 2026: What Is Driving Growth?
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Exon Skipping Therapies Market Growth From $2.81 Billion In 2026 To $5.9 Billion By 2030 At A CAGR Of 20.4%
The market size for exon skipping therapies has experienced substantial growth in recent years. This market is projected to expand from $2.34 billion in 2025 to $2.81 billion in 2026, driven by a compound annual growth rate (CAGR) of 20.1%. The historical expansion can be traced to several factors: a rise in the prevalence of Duchenne muscular dystrophy, intensified research into RNA splicing mechanisms, early regulatory approvals for antisense therapies, increased funding for rare disease research, and the growth of partnerships in biotechnology.
The exon skipping therapies market is poised for substantial growth over the next few years. It is projected to expand to $5.9 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 20.4%. This anticipated growth during the forecast period is driven by the increasing adoption of personalized genetic medicine, an expanding pipeline of exon-targeted therapies, rising investment in advanced delivery systems, broadening approvals across inherited neuromuscular disorders, and increased collaboration between research institutes and biopharmaceutical companies. Prominent trends throughout this period include advancements in antisense oligonucleotide chemistry, a heightened focus on rare genetic disorders, the expansion of combination genetic therapy approaches, growing investment in RNA-based therapeutics pipelines, and an increase in clinical trials for exon-specific mutations.
Get A Free Sample Report With In-Depth Market Insights:
Exon Skipping Therapies Market Growth Momentum: What Factors Are Shaping Demand?
The expanding incidence of genetic disorders is projected to propel the growth of the exon skipping therapies market throughout the forecast period. Genetic disorders are health conditions stemming from irregularities in an individual’s genetic material (DNA), encompassing single-gene mutations and chromosomal changes that can result in inherited or acquired illnesses. This noticeable rise in genetic disorder prevalence is primarily due to breakthroughs in diagnostic tools and the broader implementation of genetic testing and newborn screening programs, which facilitate earlier and more precise detection of previously undiagnosed instances. Exon skipping therapies are formulated to target specific genetic mutations by selectively removing defective exons during messenger RNA (mRNA) processing, thereby enabling the production of partially or fully functional proteins. This focused therapeutic strategy directly addresses the fundamental molecular origins of certain genetic conditions, particularly rare and previously untreatable ones, generating considerable clinical and commercial appeal. For instance, in October 2024, the National Health Service (NHS) England, a UK government body, initiated a landmark newborn screening program across NHS hospitals to screen numerous newborns for over 200 rare genetic conditions, with aspirations to extend screening to as many as 100,000 babies across England. Consequently, the increasing prevalence of genetic disorders is fueling the expansion of the exon skipping therapies market.
Exon Skipping Therapies Market Segmentation: How Does The Market Break Down By Category?
The exon skipping therapies market covered in this report is segmented –
1) By Product Type: Antisense Oligonucleotides, Synthetic Ribonucleic Acid Molecules, Exon-Targeted Gene Therapy Kits, Combination Therapy Formulations, Other Product Types
2) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Route Of Administration
3) By Distribution Channel: Direct Sales, Distributors, Online Pharmacies, Other Distribution Channel
4) By Application: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Spinal Muscular Atrophy, Other Inherited Diseases, Other Applications
5) By End-User: Hospitals And Clinics, Research Institutes, Biopharmaceutical Companies, Specialty Genetic Centers, Other End Users
Subsegments:
1) By Antisense Oligonucleotides: Phosphorodiamidate Morpholino Oligonucleotides, Peptide Conjugated Oligonucleotides, Gapmer Oligonucleotides, Steric Blocking Oligonucleotides, Splice Modulating Oligonucleotides
2) By Synthetic Ribonucleic Acid Molecules: Messenger Ribonucleic Acid Molecules, Small Interfering Ribonucleic Acid Molecules, Guide Ribonucleic Acid Molecules, Modified Ribonucleic Acid Molecules, Therapeutic Ribonucleic Acid Constructs
3) By Exon-Targeted Gene Therapy Kits: Viral Vector Delivery Kits, Non-Viral Delivery Kits, Plasmid-Based Gene Therapy Kits, Targeted Editing Delivery Kits, Tissue Specific Delivery Kits
4) By Combination Therapy Formulations: Gene Therapy And Drug Combination, Oligonucleotide And Small Molecule Combination, Multi-Target Genetic Therapy, Supportive Protein Therapy Combination, Sequential Genetic Therapy Formulations
5) By Other Product Types: Peptide Based Genetic Modulators, Nanoparticle Delivery Formulations, Lipid Based Delivery Systems, Targeted Molecular Complexes, Personalized Genetic Therapy Formats
Exon Skipping Therapies Market Trends Redefining Industry Growth
Leading firms in the exon skipping therapies market are increasingly prioritizing the creation of advanced treatment options, like experimental antibody-oligonucleotide conjugate (AOC) therapies, to optimize targeted drug delivery and boost dystrophin generation in individuals with Duchenne muscular dystrophy (DMD). These AOC treatments signify an advanced method that unites a monoclonal antibody and a synthetic oligonucleotide, facilitating the precise delivery of exon-skipping agents straight to muscle cells. As an example, in July 2025, Avidity Biosciences Inc., a U.S.-headquartered biotechnology firm, obtained Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for delpacibart zotadirsen (del-zota), an experimental AOC therapy designed to treat DMD in patients with specific mutations suitable for exon 44 skipping. Del-zota is composed of a specialized monoclonal antibody linked to phosphorodiamidate morpholino oligomers (PMOs), which aid in exon 44 skipping during the mRNA processing stage. This treatment is presently undergoing Phase 2 clinical development, with intentions for regulatory filing bolstered by strong biomarker and clinical effectiveness information. These progress points emphasize the increasing focus on distinct delivery systems within the exon skipping therapies market and demonstrate the transformative role of AOC technologies in developing future precision treatments for inherited neuromuscular conditions.
Exon Skipping Therapies Market Key Players Shaping Industry Direction
Major companies operating in the exon skipping therapies market are Daiichi Sankyo Company Limited, BioMarin Pharmaceutical Inc., Sarepta Therapeutics, Nippon Shinyaku Co. Ltd., Ionis Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals Inc., Entrada Therapeutics Inc., Wave Life Sciences, PepGen Inc., ProQR Therapeutics NV, NS Pharma Inc., Genethon, Astellas Gene Therapies, SQY Therapeutics, AUM Biotech Inc., Cure Rare Disease Inc., Autotelic Bio Inc., Dyne Therapeutics, Skip Therapeutics.
View The Full Exon Skipping Therapies Market Report:
Exon Skipping Therapies Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the exon skipping therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exon skipping therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.